Amneal Pharma Faces Parkinson's Candidate Setback with FDA's CRL
- July 03rd, 2023
- 253 views
Shares of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) dropped over 10% in after-hours trading due to a Complete Response Letter from the FDA regarding the company's New Drug Application for IPX203 to treat Parkinson's disease, a neurological condition characterized by involuntary and uncontrolled movements, including tremors, rigidity, and challenges with balance and coordination.
According to Amneal, the FDA requested additional information on the ingredient carbidopa, and no issues were identified in the letter regarding the efficacy or manufacturing of IPX203.
The company stated that it will work with the FDA to address the comments and move forward, and the financial guidance for 2023 remains unaffected by this development.
$AMRX was trading at $2.65 (-13.11%) in the extended session after the announcement.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Micron Technology, Jabil, and Birkenstock Earnings Preview: What to Expect
December 15th, 2024Upcoming Earnings: Synopsys, AeroVironment, and nCino in Focus
December 01st, 2024Countdown to Earnings: Salesforce, Marvell Technology, and Okta Take the Stage
December 01st, 2024Fluence Energy, Agilent Technologies, and Woodward Earnings On Deck: A Preview
November 24th, 2024Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024
Member Login